(ZEG) AstraZeneca - Ratings and Ratios
Exchange: XETRA • Country: United Kingdom • Currency: EUR • Type: Common Stock • ISIN: GB0009895292
ZEG EPS (Earnings per Share)
ZEG Revenue
ZEG: Cancer, Heart, Respiratory, Vaccines, Rare Diseases
AstraZeneca PLC is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative prescription medicines. With a diverse portfolio of products, the company addresses various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and rare diseases. AstraZenecas product lineup includes a range of treatments, such as Imjudo, Tagrisso, Imfinzi, Lynparza, Calquence, and Enhertu, among others, which are designed to meet the needs of primary and specialty care physicians.
The companys strategic focus on research and development is evident in its collaboration with Tempus to develop the largest multimodal foundation model in oncology. This partnership underscores AstraZenecas commitment to leveraging cutting-edge technology to drive innovation in cancer treatment. With a global presence, AstraZeneca serves customers in the United Kingdom, the United States, Europe, and Asia through a network of distributors and local representative offices.
From a technical analysis perspective, AstraZenecas stock (ZEG) is currently trading at €127.65, with a 20-day simple moving average (SMA) of €123.67 and a 50-day SMA of €125.77. The stocks 200-day SMA stands at €133.16, indicating a potential resistance level. The average true range (ATR) is 2.59, representing a 2.03% daily volatility. Given the current price action and technical indicators, a potential short-term target could be €130, while a break below €123.67 may signal a downward trend.
Fundamentally, AstraZenecas market capitalization stands at €192.53 billion, with a price-to-earnings (P/E) ratio of 28.23 and a forward P/E of 15.55. The companys return on equity (RoE) is 19.18%, indicating a strong ability to generate profits. Considering the fundamental data and technical analysis, a forecast for AstraZenecas stock could be: a short-term consolidation between €125 and €130, followed by a potential breakout above €133.16, driven by the companys continued innovation and strong product pipeline. However, a decline below €123.67 could signal a correction, potentially targeting €115.
Additional Sources for ZEG Stock
ZEG Stock Overview
| Market Cap in USD | 231,093m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
ZEG Stock Ratings
| Growth Rating | 33.3 |
| Fundamental | 77.3 |
| Dividend Rating | 49.8 |
| Rel. Strength | -5.52 |
| Analysts | - |
| Fair Price Momentum | 109.85 EUR |
| Fair Price DCF | 126.46 EUR |
ZEG Dividends
| Dividend Yield 12m | 2.56% |
| Yield on Cost 5y | 4.08% |
| Annual Growth 5y | 1.58% |
| Payout Consistency | 96.8% |
| Payout Ratio | 62.3% |
ZEG Growth Ratios
| Growth Correlation 3m | -22.5% |
| Growth Correlation 12m | -59.8% |
| Growth Correlation 5y | 87.3% |
| CAGR 5y | 8.96% |
| CAGR/Max DD 5y | 0.32 |
| Sharpe Ratio 12m | 1.01 |
| Alpha | -15.03 |
| Beta | 0.104 |
| Volatility | 20.78% |
| Current Volume | 10.5k |
| Average Volume 20d | 10.6k |
As of June 16, 2025, the stock is trading at EUR 129.35 with a total of 10,510 shares traded.
Over the past week, the price has changed by +0.98%, over one month by +7.03%, over three months by -8.84% and over the past year by -10.32%.
Yes, based on ValueRay´s Fundamental Analyses, AstraZeneca (XETRA:ZEG) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 77.29 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZEG is around 109.85 EUR . This means that ZEG is currently overvalued and has a potential downside of -15.08%.
AstraZeneca has no consensus analysts rating.
According to our own proprietary Forecast Model, ZEG AstraZeneca will be worth about 118.6 in June 2026. The stock is currently trading at 129.35. This means that the stock has a potential downside of -8.28%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 118.6 | -8.3% |